Wobenzym, a combination of proteolytic enzymes and the antioxidant rutin, works systemically by targeting various tissues and organs in the body. Wobenzym is targeted at modulating the immune response to restore a healthy balance between anti-inflammatory and pro-inflammatory cytokines.[1] Some possible side effects have been reported in medical literature.[2][3]

Wobenzym was first developed in the 1950's by Austrian physician Max Wolf,[4] and is today marketed by Nestlé Health Science.[5]

In clinical studies, oral administration of proteolytic enzymes to healthy volunteers resulted in immunomodulatory effects and systemic therapy before and after exhaustive exercise increased maximal concentric strength, and had favorable effects on inflammatory, metabolic and immune biomarkers. In a randomized trial of subjects with moderate-to-severe knee osteoarthritis, oral proteolytic enzymes were found to have comparable effectiveness as diclofenac in relieving pain and increasing function.[6]

See also

References

  1. ↑ "Wobenzym Tablets Information". Drugs.com.
  2. ↑ "Acute circulatory shock following administration of the non-regular enzyme preparation Wobe-Mugos". Medscape.com. 1991-12-07. Retrieved 2016-03-31.
  3. ↑ "Probable coumarin poisoning upon ingestion of an anti-inflammatory agent". Medscape.com. 1995-07-01. Retrieved 2016-03-31.
  4. ↑ "Wobenzym Brochure" (PDF). douglaslabs.com. Retrieved 13 September 2023.
  5. ↑ "Nestle to acquire supplement and vitamin maker Atrium Innovations for $2.3bn". 10 December 2017.
  6. ↑ "Proteolytic enzymes | Memorial Sloan Kettering Cancer Center".
This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.